BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
November 16, 2020 07:00 ET
|
BeyondSpring, Inc.
Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015Study met statistically significant improvement in key...
BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
November 13, 2020 16:46 ET
|
BeyondSpring, Inc.
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
November 13, 2020 07:00 ET
|
BeyondSpring, Inc.
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics (“the...
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
October 14, 2020 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics Inc. (the “Company” or “Seed Therapeutics”), a global research company and BeyondSpring subsidiary focused on harnessing and engineering...
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
October 12, 2020 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...
JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
September 29, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
New Data Highlights BeyondSpring’s Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19
September 24, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
September 22, 2020 08:30 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia...
BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
September 11, 2020 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
September 08, 2020 07:00 ET
|
BeyondSpring, Inc.
- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention...